Nikhil Thatte

Nikhil Thatte is a Senior Principal with Lumira Ventures and been with the firm since March 2019. Nikhil is primarily focused on next generation modalities including protein degradation, gene therapy, cell therapy, and gene editing. Nikhil represents Lumira Ventures as a board member or observer with a number of its portfolio companies including Specific Biologics, Alpina Biotechnology, BioTheryx, XyloCor Therapeutics and PIC Therapeutics and co-led Lumira’s investment and successful exit in ESSA Pharma. Prior to Lumira Ventures, Nikhil was a Director with DRI Capital, a pioneer in royalty monetization solutions, where he managed relationships with inventors, academics and companies, and played a key role in the due diligence process as part of the investment team. Prior to DRI Capital, Nikhil was a Consultant with ZS Associates, a global marketing and sales consulting firm where he provided expertise to over 20 pharmaceutical and biotechnology clients across a broad range of projects and therapeutic areas. He also served as an Analyst with Bayer AG and Health Canada.

Nikhil holds a Bachelor’s Degree in Chemical Engineering from McGill University.